Ensign Peak Advisors Inc trimmed its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 4.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,163,769 shares of the biopharmaceutical company’s stock after selling 261,578 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.09% of Pfizer worth $144,482,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. FAS Wealth Partners Inc. grew its stake in Pfizer by 1.3% in the 2nd quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock worth $736,000 after acquiring an additional 342 shares during the period. Sachetta LLC increased its stake in Pfizer by 7.3% in the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 342 shares during the last quarter. Ironvine Capital Partners LLC lifted its position in Pfizer by 2.1% during the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after buying an additional 353 shares during the period. Secure Asset Management LLC boosted its stake in Pfizer by 0.6% in the 2nd quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock worth $1,632,000 after buying an additional 353 shares during the last quarter. Finally, Patrick M Sweeney & Associates Inc. grew its holdings in Pfizer by 0.8% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock valued at $1,180,000 after buying an additional 355 shares during the period. 68.36% of the stock is owned by institutional investors.
Pfizer Stock Down 0.8 %
PFE stock opened at $29.42 on Friday. The firm has a market cap of $166.71 billion, a price-to-earnings ratio of -490.25, a PEG ratio of 1.05 and a beta of 0.68. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a fifty day moving average price of $29.36 and a two-hundred day moving average price of $28.22.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.71%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, September 16th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.
Read Our Latest Stock Report on Pfizer
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
- Five stocks we like better than Pfizer
- With Risk Tolerance, One Size Does Not Fit All
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 9/16 – 9/20
- Top Stocks Investing in 5G Technology
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.